The pharmaceutical community is buzzing by retatrutide, a new dual GIP and GLP-1 agonist that’s showing remarkable results in early studies . This treatment works by replicating natural hormones to impact appetite and promote feelings of fullness , ultimately contributing to considerable fat redu